Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate.

Authors

  • E. G. Kuryk ГНУ «Научно-практический центр профилактической и клинической медицины» Государственного управления делами, Киев, Ukraine
  • E. O. Litvak ГНУ «Научно-практический центр профилактической и клинической медицины» Государственного управления делами, Киев, Ukraine
  • B. V. Chabrat ГНУ «Научно-практический центр профилактической и клинической медицины» Государственного управления делами, Киев, Ukraine
  • B. M. Lysenko ГНУ «Научно-практический центр профилактической и клинической медицины» Государственного управления делами, Киев, Ukraine

DOI:

https://doi.org/10.26641/1997-9665.2015.3.42-47

Keywords:

leiomyomas of the uterus, progesterone receptors, proliferation, apoptosis, ulipristal acetate

Abstract

Background. Uterine leiomyoma is one of the most common benign tumors of the female genital organs. The main conservative treatment of leiomyoma is progesterone receptor blockers that suppress myoma growth and may lead to its regression. Objective. To study the immunohistochemical features of myoma tissue in patients with uterine leiomyoma after treatment with selective progesterone modulator - ulipristal acetate. Methods. Leiomyoma tissue obtained from 9 patients after ulipristal acetate treatment were investigated. Group for comparison - leiomyoma from patients without hormonal therapy. Immunohistochemical study of progesterone and estrogen receptors, proliferative activity marker Ki-67 and inhibitor of apoptosis Bcl-2 was performed. Results. In the group of patients without preoperative hormonal treatment progesterone receptors were expressed in 76,4±6,8% of the nuclei, estrogen receptors - in 32,8±2,6%. In the group of patients after treatment with ulipristal acetate there was a significant decrease of progesterone receptor expression – 36,8±1,28% (p <0,05) and a nonsignificant decrease of estrogen expression – 30,7±3,4% (p> 0,05) . Bcl-2 in the control group was found in 65,4±7,2% cells, in leiomyoma after treatment there was a significant decrease of bcl-2 – 42,6±3,2% (p <0, 05). In leiomyomas without hormonal treatment Ki-67 was determined in 11,8% of the nuclei of smooth muscle cells, and in leiomyomas after ulipristal acetate – in 7,2% leiomyoma cells. Conclusions. In patients after three months of ulipristal acetate treatment there was a significant decrease of expression of progesterone receptor, bcl-2, and Ki-67. Taken together these data evidence reduced action of progesterone on leiomyoma cells, induction of apoptosis and decreased proliferation processes that may cause involution of fibroids.

References

  1. Radzinskiy VE, Totchiyev GF. [Uterine myoma: course for organ preservation. Newslettes]. M: Publishing office of StatusPraesens journal; 2014. P. 24. Russian.
  2. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, Sasaki H, Morikawa A, Maruo T. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010 May;28(3):260-73. doi: 10.1055/s-0030-1251483. PMID: 20414849
  3. Talaulikar VS, Manyonda I. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2012 Dec;165(2):135-40. doi: 10.1016/j.ejogrb.2012.07.023. PMID: 22901974.
  4. Talaulikar VS, Manyonda IT. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Ther 2012;29(8):655–63. doi: 10.1007/s12325-012-0042-8. PMID:22903240
  5. Biglia N, Carinelli S, Maiorana A, D'Alonzo M, Lo Monte G, Marci R. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther. 2014 Feb 20;8:285-92. doi: 10.2147/DDDT.S54565. PMID: 24591818.
  6. Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, Barlow DH, Palacios S, Donnez O, Bestel E, Osterloh I, Loumaye E; PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014 Jun;101(6):1565-73.e1-18. doi: 10.1016/j.fertnstert.2014.02.008. PMID: 24630081.
  7. Berger C, Boggavarapu NR, Menezes J, Lalitkumar PG, Gemzell-Danielsson K. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Hum Reprod. 2015 Apr;30(4):800-11. doi: 10.1093/humrep/dev030. PMID: 25740886.
  9. Tikhomirov AL, Zayratyants OV. [A clinico-morphological characteristic of uterine myoma after using the selective progesterone receptor modulator ulipristal]. Voprosy ginekologii, akusherstva i perinatologii.2014, 13(1):67-72. Russian.
  10. Tikhomirov AL, Kazenashev VV, Zayratyants OV, Manukhin IB. [First clinical-morphological tendencies of the treatment ofpatients with myoma of womb with ulipristal acetate]. Gynecology (Moscow). 2014;16(2):29-33. Russian.
  11. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod. 1999 Nov;14(11):2844-50. PMID: 10548634.
  12. Potapov VA, Donskaya YuV, Medvedev MV. [Histological and immunohistochemical evalu-ation of leiomyoma and endometrial tissue in pa-tients with uterine leiomyoma and endometrial hy-perplasia]. Morphologia. 2014;8(1):80-4. Ukrainian.
  13. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009 Aug;24(8):1870-9. doi: 10.1093/humrep/dep100. PMID: 19389793.
  14. Murdoch М, Roberts M. Selective proges-terone receptor modulators and their use within gynaecology. The Obstetrician & Gynaecologist. 2014;16(1):46-50. DOI: 10.1111/tog.12072.

Downloads

How to Cite

Kuryk, E. G., Litvak, E. O., Chabrat, B. V., & Lysenko, B. M. (2015). Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate. Морфологія / Morphologia / Morfologìâ, 9(3), 42–47. https://doi.org/10.26641/1997-9665.2015.3.42-47

Issue

Vol. 9 No. 3 (2015)

Section

Статті

License

Copyright (c) 2018 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.